eQMS for Cell and Gene Therapy Catapult stays with Ideagen
- Cell and Gene Therapy Catapult
- London
- Below threshold - without competition
- 31 August 2026 to 30 August 2028
Cell and Gene Therapy Catapult renewed its subscription to Ideagen's electronic quality management system (eQMS). Ideagen keeps the work, which covers continued access to the hosted platform plus maintenance and support.
The Catapult awarded the renewal directly, without a competition, in July 2026. The two-year contract is worth £120,598, or £144,717 including VAT, and runs to August 2028.
Contract ends August 2028
- What
- Quality management system (QMS) software
- Supplier
- Ideagen
- Value
- £120,598
- How it was bought
- Below threshold - without competition
- Dates and next
- Aug 2026 to Aug 2028